Document is current
Any future updates will be listed below
-
Authors
Ipseiz, Natacha
Pickering, Robert J https://orcid.org/0000-0003-3332-9868
Rosas, Marcela
Tyrrell, Victoria J
Davies, Luke C
Orr, Selinda J
Czubala, Magdalena A
Fathalla, Dina
Robertson, Avril AB
Bryant, Clare E https://orcid.org/0000-0002-2924-0038
O'Donnell, Valerie
Taylor, Philip R https://orcid.org/0000-0003-0163-1421
-
Funding
Funding for this research was provided by:
Wellcome Trust (107964/Z/15/Z)
Wellcome Trust (103973/Z/14/Z)
Wellcome Trust (108045/Z/15/Z)
Wellcome Trust and the Royal Society (099953/Z/12/Z)
UK Research and Innovation|Medical Research Council (Dementia Research Institute)
- License Information
-
More Information
Article History
Received: 13 September 2019
Revised: 28 April 2020
Accepted: 30 April 2020
First Online: 2 June 2020
Conflict of interest
: AABR is a co‐inventor on granted patents (US 10,538,487, EP 3259253) and patent applications (WO2018215818, WO2017140778, WO2016131098) for NLRP3 inhibitors, which are licensed to Inflazome Ltd, a company headquartered in Dublin, Ireland. Inflazome is developing drugs that target the NLRP3 inflammasome to address unmet clinical needs in inflammatory disease.
